par Califano, Raffaele;Karamouzis, M V;Banerjee, Susana;de Azambuja, Evandro
;Guarneri, V;Hutka, M;Jordan, Karin;Kamposioras, K;Martinelli, E;Corral-Juan, Marc;Postel-Vinay, S;Preusser, Matthias;Porcu, L;Torri, Valter
Référence Lung cancer, 85, 1, page (74-80)
Publication Publié, 2014-07
;Guarneri, V;Hutka, M;Jordan, Karin;Kamposioras, K;Martinelli, E;Corral-Juan, Marc;Postel-Vinay, S;Preusser, Matthias;Porcu, L;Torri, ValterRéférence Lung cancer, 85, 1, page (74-80)
Publication Publié, 2014-07
Article révisé par les pairs
| Résumé : | Early stage Non-Small Cell Lung Cancer (NSCLC) is potentially curable with surgery. ESMO guidelines recommend cisplatin-based adjuvant chemotherapy (CT) for completely resected stage II-III NSCLC. There is limited evidence for the use of adjuvant CT and/or radiotherapy (RT) in incompletely resected (R1) early stage NSCLC. |



